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Recommended by Elijah Dixon
Liver resection is the only curative treatment for patients with colorectal liver metastases (CLMs). Neoadjuvant chemotherapy can
improve resectability but has a potential harmful eﬀect on the nontumorous liver. Patients with chemotherapy-induced hepatic
injury undergoing liver surgery have higher risks of post-resectional morbidity. We present two cases of patients without pre-
existent liver disease treated with oxaliplatin-based chemotherapy followed by surgical resection of their CLMs. Their intra-
operative liver specimen showed morphologic abnormalities characteristic of nodular regenerative hyperplasia (NRH). NRH
led to portal hypertension in both patients that resulted in deleterious post-resectional complications and death of one patient.
Interestingly,theotherpatientunderwenttworepeatnonanatomicliverresectionsbecauseofrecurrentCLMs.Theintra-operative
liverspecimenstillshowedsignsofNRHandsinusoidalcongestion,butthepost-resectionalcourseswereuneventful.Nevertheless,
caution is recommended in patients with suspected NRH. Careful volumetric analysis should guide the operative strategy. When
future remnant liver volume is regarded insuﬃcient, portal vein embolization or restrictive surgery should be considered.
Copyright © 2009 Maartje A. J. van den Broek et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Colorectal liver metastases (CLMs) develop in 50–60% of
patients with colorectal carcinoma. Resection remains the
only curative treatment, but just 15–20% of patients are
initially eligible for resection. Administration of neoadju-
vant chemotherapy can improve resectability in 15–30% of
patients with initially unresectable disease [1]. In addition,
perioperativechemotherapyhasalsobeenproventoelongate
progression-free survival in patients with initially resectable
disease [2]. However, recent reports show a potential harm-
ful eﬀect of oxaliplatin or irinotecan-based neoadjuvant
chemotherapyonthenontumorousliver[3–5].Patientswith
histologically proven chemotherapy-related hepatic injury
undergoingliversurgeryhavehigherrisksofpost-resectional
morbidity [6] and mortality [5].
Here, we present two cases of patients without pre-
existent liver disease preoperatively treated with oxaliplatin
and capecitabine because of CLMs who developed nodu-
lar regenerative hyperplasia (NRH) of the liver causing
deleterious complications after major hemihepatectomy.
Interestingly, one of these patients underwent limited repeat
resections after 12 and 18 months because of recurrent
CLMs, after which the clinical courses were uneventful.
2. Patient Cases
Case 1. A 68-year-old man was referred to our hospi-
tal because of synchronous CLMs. His medical history
revealed a colorectal carcinoma (pT3N0M1) treated by
right hemicolectomy. Neoadjuvant chemotherapy consisting
of 6 cycles of oxaliplatin (130mg/m2) and capecitabine
(1000mg/m2 2-times daily) was initiated after resection
of the colorectal primary. The patient had no history
of liver disease and computed tomography (CT) scan2 Case Reports in Medicine
Table 1: Laboratory values of the patients described in Case 1
and Case 2 before and after administration of oxaliplatin-based
neoadjuvant chemotherapy.
Case 1 Case 2
Before Ctx After Ctx Before Ctx After Ctx
Alkaline phosphatase
(U/L)
205 237 328 205
γ-glutamyltransferase
(U/L)
50 42 233 90
ASAT (U/L) n.a. 59 61 79
ALAT (U/L) n.a. 23 91 57
Bilirubin (total)
(μmol/L)
n.a. 39 12 21
INR n.a. n.a. n.a. n.a.
Ctx: chemotherapy; ASAT: aspartate aminotransferase; ALAT: alanine
aminotransferase; INR: international standardized ratio; n.a.: not available
did not reveal any signs of cirrhosis, portal hyperten-
sion, parenchymal abnormalities, or other liver pathology.
Liver function tests prior to and after administration of
chemotherapy are depicted in Table 1. CT images showed
a partial response of the CLMs with metastases remaining
in segments IVb, VI, and VIII for which an extended
right hemihepatectomy was the only realistic curative
treatment. As a remnant liver volume of only 18% was
calculated by CT volumetry, preoperative right portal vein
embolization was performed. Five weeks later, remnant
liver volume increased up to 28% which was regarded
just suﬃcient for safe hemihepatectomy. An extended
right hemihepatectomy with Roux-Y reconstruction was
performed as detailed previously [7] .Ab l u i s ha p p e a r -
ance of the liver was noticed intra-operatively without
signs of portal hypertension. Histologic examination of the
liver specimen showed sinusoidal congestion and nodula-
rity characteristic of NRH. The postoperative course was
uncomplicated till day four. From then on, bilirubin and
prothrombin time increased reﬂecting post-resectional liver
failure. Acute upper gastrointestinal haemorrhage occurred
on day eight for which early management consisted of emer-
gent endoscopy that showed bleeding from grade IV gastro-
oesophageal varices. A CT scan performed on the same
day showed impressive portacaval collateral shunting in the
splanchnic area (see Figure 1). Unfortunately, haemorrhage
recurred several hours later and second endoscopy failed
to control it. Therefore, a Sengstaken-Blakemore tube was
inserted and a laparotomy was performed during which the
stomach was packed. Because of ongoing deterioration, a
distal splenorenal shunt was created one day later to relieve
portal pressure.
Despite these eﬀorts, the patient died several hours
after relaparotomy because of multiorgan failure secondary
to haemorrhagic shock. Postmortem evaluation revealed
NRH of the liver combined with hepatic congestion and
infarction as well as extensive collateral vessels in the
splanchnic region. There was no evidence for surgery-
related technical failure like portal or hepatic vein obstruc-
tion.
∗
∗ ∗
Figure 1: Contrast-enhanced computed tomography scan per-
formed 8 days postoperatively (Case 1). The stomach (white
arrow) is ﬁlled with blood after upper gastrointestinal bleeding
from gastro-oesophageal varices secondary to portal hypertension.
Multiple large collateral veins run along the stomach and spleen
(white asterisk).
Case 2. A 51-year-old man consulted our hospital because
of synchronous CLMs after sigmoid resection for colorectal
carcinoma (pT3N0M1) elsewhere. The patient received
six cycles of oxaliplatin (130mg/m2) and capecitabine
(1000mg/m2 2-times daily) subsequent to resection of his
primary tumour. There was no history of liver disease.
The evolution of the liver function tests of the patient
described in this case is shown in Table 1. CT imaging
showed tumour regression after chemotherapy with metas-
tases remaining in segments III, IVa and the right hemiliver.
A right hemihepatectomy with metastasectomy of tumour
from segments III and IVa was performed without biliary
reconstruction [7]. Remnant liver volume was estimated
intraoperatively to be 35% with a bluish appearance of the
liver remnant. Histologic examination of the liver specimen
showed a nodular appearance with hepatic congestion
characteristic of NRH (Figures 2 and 3). The postoperative
course was complicated by bile leakage treated by CT-
guided percutaneous drainage and ERCP-guided common
bileductstenting.Bilirubinandprothrombintimedecreased
during admission and the patient was discharged 14 days
postoperatively. Two days after discharge, the patient was
readmitted in his hometown hospital because of portal
hypertension leading to oesophageal variceal bleeding with
hepatic encephalopathy treated by endoscopic band ligation
and conservative measures, respectively. Laboratory values
normalized steadily consistent with an improvement of
the patient’s clinical and mental status. Full recovery was
accomplished after two months.
One year afterwards, the patient presented himself with
multiple recurrent CLMs in segments II and III for which
he received 3 cycles of irinotecan (300mg/m2)p r i o rt o
liver surgery. Preoperative diagnostic liver biopsy showed
minimal nodularity and steatosis without indications for
NRH or steatohepatitis. The patient underwent treatment ofCase Reports in Medicine 3
Figure 2:Overviewoftheintra-operativelyobtainedliverspecimen
(Case2)inwhichtheliverhasadisturbedarchitecturewithnodular
appearance of liver parenchyma (white arrows) characteristic of
nodular regenerative hyperplasia. Areas with sinusoidal congestion
are also present (black arrow). Hematoxylin and eosin, original
magniﬁcation 50x.
Figure 3: Detail of the intra-operative liver specimen (Case 2)
showing nodular regenerative hyperplasia in which a regenerative
nodule (white arrow) is bordered by irregular aligned small-sized
hepatic trabeculae (black arrows). Hematoxylin and eosin, original
magniﬁcation 100x.
theCLMsbynonanatomicalwedgeresectionsfollowedbyan
uneventful clinical course. Histopathologic examination of
intra-operative liver specimen showed signs consistent with
NRH again.
Eighteen months later, another recurrent CLM was
resectedfromsegmentIVbafterwhichtheclinicalcoursewas
uneventful.Noneoadjuvantchemotherapywasadministered
prior to surgery this time as the CLM was deemed resectable
without the need for downsizing by means of chemotherapy.
Histopathologic examination of the nontumorous liver did
not reveal signs for NRH anymore. However, some areas
of the nontumorous liver did still show minimal sinusoidal
congestion.
3. Discussion
Chemotherapy is an essential element in the multimodal
approach of CLMs. However, chemotherapy consisting of
either irinotecan or oxaliplatin has been associated with the
development of histologic lesions in the nontumorous liver
that are related to post-resectional complications [2, 5, 6].
Irinotecan has been shown to induce hepatic inﬂammation
classiﬁed as chemotherapy-associated steatohepatitis which
is associated with increased 90-day mortality after liver
surgery [5, 8]. Oxaliplatin is related to vascular lesions
classiﬁed as sinusoidal obstruction syndrome (SOS) and,
sporadically, also to NRH [3, 4, 6, 9, 10]. Recently, Nakano et
al. showed a signiﬁcant association between the presence of
vascular lesions in the nontumorous liver secondary to oxali-
platinandincreasedmorbidityaftermajorhemihepatectomy
[6].
NRH of the liver is characterized by the diﬀuse presence
of regenerative nodules made up of hyperplastic hepatocytes
less than 3mm in diameter without ﬁbrous septa [11]. The
liver parenchyma between the nodules contains atrophic
hepatocytes and shows signs of sinusoidal dilatation and
congestion (Figures 2 and 3). Usually, these lesions are cli-
nically asymptomatic but they can be associated with portal
hypertension, splenomegaly, and bleeding from oesophageal
varices [12]. Liver function is usually preserved in patients
suﬀering from NRH, although slight increases in alka-
line phosphatase or aspatate aminotransferase might be
noticed.
The parenchymal injury characteristic of NRH originates
from a heterogeneous perfusion of the liver secondary to
obliterative lesions in either the portal vein or hepatic
sinusoids [11, 13]. Oxaliplatin-based chemotherapy has
at o x i ce ﬀect on sinusoidal endothelial cells resulting in
sinusoidaldilatation,congestion,andobstruction.Depletion
of sinusoidal glutathione and activation of matrix me-
talloproteinases by oxaliplatin have been postulated as
pathogenic factors in the development of these sinusoidal
lesions [13]. Furthermore, it has been hypothesized that
the sinusoidal lesions impair hepatic regeneration [4, 14]
and aggravate portal pressure. The extent of reversibility of
these lesions is still uncertain; patients undergoing repeat
resection because of recurrent CLMs still showed sinusoidal
dilatation or (progressive) ﬁbrosis [4]. On the other hand,
a longer time interval between neoadjuvant chemotherapy
and surgical resection seemed to decrease the incidence of
sinusoidal injury [6].
It is imperative to recognize the presence of SOS or
NRH prior to hemihepatectomy. The diagnostic value of a
preoperative liver biopsy seems to be minimal because of
sampling error resulting in a high false-negative result rate
and therefore, suspicion is merely based on the patient’s
history, preoperative liver function, and intra-operative
macroscopic aspect. In this respect, 4 factors independently
associated with sinusoidal injury have been identiﬁed [6].
These include female gender, administration of 6 or more
cycles of oxaliplatin-based chemotherapy, abnormal value
of preoperative aspartate aminotransferase (>36IU/L), and
indocyanine green retention rate at 15 minutes of >10%.4 Case Reports in Medicine
Vauthey et al. suggested to perform a preoperative diagnostic
laparoscopy to identify a bluish appearance of the liver
[5].
It could be postulated that, considering the hepato-
toxicity of neoadjuvant chemotherapy, initial liver surgery
followed by adjuvant chemotherapy might be the treatment
of choice in patients with clearly resectable CLMs [15].
However, the eﬀects on disease-free and long-term survival
should be evaluated in adequately powered randomized
controlled trials. In case of unresectable or recurrent CLMs
preoperatively treated with oxaliplatin-based chemotherapy,
cautionisrecommendedwhenanextensivehepaticresection
is scheduled and SOS or NRH are suspected. Even if the time
interval between chemotherapeutic treatment and surgical
resection is long, SOS or NRH might still be present.
Careful volumetric analysis of future remnant liver volume
should guide the operative strategy. Either preoperative
portal vein embolization and/or restrictive surgery should
be considered when the future remnant liver volume is
regarded insuﬃcient. The safety limit for future remnant
liver volume after neoadjuvant chemotherapy treatment
would be between 30% and 40%; however, this needs careful
prospective validation.
Future research should be focussed on assessment of the
optimal duration of chemotherapeutic treatment and timing
of liver surgery as well as the development of reliable scree-
ning methods and strategies to protect the nontumorous
liver from the deleterious eﬀects of neoadjuvant chemother-
apy.
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